Clinical trial • Phase I • Endocrinology
NEX-22A for Type 2 diabetes
Phase I trial of NEX-22A for Type 2 diabetes. 9 participants.
Overview
- Trial Therapeutic Area
- Endocrinology
- Trial Disease
- Type 2 diabetes
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 04-12-2023
- First CTIS Authorization Date
- 21-02-2024
Trial design
Phase I trial across 1 site in Germany.
- Target Sample Size
- 9
- Trial Duration For Participant
- 77
Eligibility
Recruits 9 Vulnerable populations not selected; no specific consent or assent handling described..
- Vulnerable Population
- Vulnerable populations not selected; no specific consent or assent handling described.
Recruitment
- Planned Sample Size
- 9
- Recruitment Window Months
- 2
- Consent Approach
- No information on informed consent or assent; not described. Vulnerable populations not selected.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 9
Germany
- Earliest CTIS Part Ii Submission Date
- 15-01-2024
- Latest Decision Or Authorization Date
- 21-02-2024
- Processing Time Days
- 37
- Number Of Sites
- 1
- Number Of Participants
- 9
Sites
- Site Name
- PROFIL Institut fuer Stoffwechselforschung GmbH
- Contact Person Name
- Grit Andersen
- Contact Person Email
- grit.andersen@profil.com
Sponsor
Primary sponsor
- Full Name
- Nanexa AB
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Sweden
Investigational products
- Investigational Product Name
- NEX-22A
Related trials
Other published trials that may interest you.